About the Company
NeurAxis, Inc
BUSINESS DESCRIPTION
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. NeurAxis is dedicated to advancing the science with its’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. We believe that superior science, evidence-based research, and building on its unparalleled body of clinical evidence is necessary for adoption by the medical...
NeurAxis, Inc News
-
NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase...
09/13/2023 01:00 PMCARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company comm...
-
EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life...
09/12/2023 02:15 PMNeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontie...
-
NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves ...
09/12/2023 01:00 PMCARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company comme...
-
NeurAxis Highlights Pediatric Post-Concussion Clinical Study...
08/29/2023 01:00 PMCARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commer...
-
NeurAxis Highlights Strength of its Board of Directors...
08/24/2023 01:00 PMCARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company comme...
-
NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adole...
08/22/2023 01:00 PMCARMEL, Ind., Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company comme...
-
NeurAxis Announces Over $8 Million in IB-Stim™ Revenue...
08/17/2023 01:02 PMCARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commerc...
-
NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness...
08/15/2023 01:00 PMCARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commerc...
-
Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc....
08/11/2023 01:30 PMGoldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new researc...
Disclaimer: